Brain Cancer

Erin Murphy, MD, associate staff, Department of Radiation Oncology, Cleveland Clinic, discusses a study examining prognostic factors of patients with glioma.

David Reardon, MD, discusses the ReACT study and the potential of rindopepimut and other immunotherapy agents for the treatment of patients with brain cancers, specifically glioblastoma.

Michael Lim, MD, Director of Brain Tumor Immunotherapy, Associate Professor of Neurosurgery, Johns Hopkins Medicine, discusses toxicities associated with checkpoint inhibitors for the treatment of glioblastoma.

Mark R. Gilbert, MD, senior investigator, chief, Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, discusses the use of precision medicine in treating patients with glioblastoma.

The deployment of precision medicine to develop safe and effective therapies to treat malignant brain tumors is an effort that poses both opportunities and challenges.

An international coalition of experts is planning an innovative clinical trial aimed at speeding up the development of new treatments for patients with glioblastoma multiforme, putting into motion a biomarker-driven approach that has been employed in other malignancies.

Hideho Okada MD, PhD, discusses the need for a new immunotherapy response assessment in euro-oncology. Okada presented on this topic at the 2015 Annual Meeting of the Society for Neuro-Oncology.

A pilot study of the efficacy of CAR T-cell therapy in patients with EGFRvIII-positive glioblastoma multiforme (GBM) has generated encouraging findings.

Maciej M. Mrugala, MD, PhD, discusses a retrospective analysis looking at adding cycles of treatment with temozolomide in newly diagnosed patients with glioblastoma.

Treatment with the immunotherapy rindopepimut plus bevacizumab resulted in a 47% reduction in the risk of death compared with bevacizumab and a control for patients with relapsed glioblastoma multiforme.

Amy B. Heimberger, MD, discusses the potential of FGL2 as a multi-modality regulator of tumor-mediated immune suppression in patients with glioblastoma.

Findings from a subgroup of patients enrolled in a phase II study assessing the dendritic vaccine ICT-107 for patients with HLA-A2+ glioblastoma multiforme merit further exploration in a phase III study.

John H. Sampson, MD, PhD, MBA, MHSc, discusses results from cohort 1 of the CHECKMATE-143 trial.

There are reasons to suggest that immune checkpoint inhibitors may be successful against central nervous system tumors, including glioblastoma.

The addition of Optune to chemotherapy and/or bevacizumab improved survival in patients with recurrent glioblastoma multiforme.

David Reardon, MD, discusses updated survival findings from the phase II ReACT trial, which analyzed rindopepimut (CDX-110) plus bevacizumab for the treatment of relapsed glioblastoma.

As immunotherapy begins to be studied across central nervous system tumors it becomes increasingly important for practitioners to understanding the unique adverse event profiles associated with these agents.

Yael Cohen, MD, vice president of Clinical Development at VBL Therapeutics Pharmaceuticals, discusses VB-111, a highly targeted anti-angiogenic agent that is being investigated in several tumor types.

The FDA has approved Optune in combination with adjuvant temozolomide as a treatment for patients with newly diagnosed glioblastoma multiforme following surgery, chemotherapy, and radiation therapy.

David Piccioni, MD, PhD, assistant professor, Neuroscience and Neuro-Oncology, UC San Diego Health, discusses tumor profiling of brain metastases of patients with non-small cell lung cancer, breast cancer, and melanoma.

Blockade of the PD-1/PD-L1 pathway is a novel and attractive treatment approach to many cancers, including malignant glioma, because of its potential to restore anti-tumor immunity.

Lenalidomide in combination with rituximab and as maintenance monotherapy is highly active in patients with relapsed/refractory central nervous system non-Hodgkin lymphoma.